Complete response letter for GSK/XenoPort's Horizant over cancer concern
This article was originally published in Scrip
The US FDA has issued GlaxoSmithKline and XenoPort a complete response letter for their non-dopaminergic restless legs syndrome (RLS) therapy, Horizant (gabapentin enacarbil extended-release, previously known as Solzira).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.